Exelixis (EXEL) Return on Capital Employed (2011 - 2026)
Exelixis (EXEL) recorded quarterly Return on Capital Employed of 39.89% in Q2 2026, up 11.07% quarter-over-quarter from 35.92% in Q1 2026, and up 933.0% on a YoY basis from 3.86% in Q2 2025.
Exelixis (EXEL) Return on Capital Employed (2011 - 2026) Analysis & Trends
Exelixis' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 39.89% for Q2 2026.
- In Q2 2026, Return on Capital Employed rose 933.0% year-over-year to 39.89%; the TTM figure through Apr 2026 stood at 39.89% (up 933.0% YoY), while the FY2026 annual figure was 35.02%, up 1123.0% from the prior year.
- Return on Capital Employed was 39.89% for Q2 2026 at Exelixis, up from 35.92% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 39.89% in Q2 2026 to a low of 1.53% in Q3 2023.
- Historically, Return on Capital Employed has averaged 17.97% across 5 years, with a median of 15.13% in 2024.
- The sharpest annual moves came in 2023 and 2025: Return on Capital Employed sank 1250 bps in 2023, then soared 2370 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 7.48% in 2022, then dropped by 11 bps to 6.66% in 2023, then jumped by 218 bps to 21.16% in 2024, then jumped by 59 bps to 33.66% in 2025, then grew by 19 bps to 39.89% in 2026.
- The last three Return on Capital Employed figures came in at 39.89% (Q2 2026), 35.92% (Q1 2026), and 33.66% (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -107.40% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -50.43% |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | 39.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 39.89% |
| Jan 2, 2026 | 35.92% |
| Oct 3, 2025 | 33.66% |
| Jul 4, 2025 | 28.90% |
| Apr 4, 2025 | 30.56% |
| Jan 3, 2025 | 23.71% |
| Sep 27, 2024 | 21.16% |
| Jun 28, 2024 | 15.13% |
| Mar 29, 2024 | 6.86% |
| Dec 29, 2023 | 6.66% |
| Sep 29, 2023 | 1.53% |
| Jun 30, 2023 | 5.04% |
| Mar 31, 2023 | 5.29% |
| Dec 30, 2022 | 7.48% |
| Sep 30, 2022 | 14.03% |
| Jul 1, 2022 | 13.66% |
| Apr 1, 2022 | 16.02% |
| Dec 31, 2021 | 13.13% |
| Oct 1, 2021 | 9.09% |
| Jul 2, 2021 | 4.95% |